the development of the automatical evaulation of MDS-UPDRS-III in Parkinson's disease

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400081206

Enrollment

Unknown

Registered

2024-02-26

Start date

2024-02-26

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

parkinson's disease

Interventions

the parkinson's disease group:None

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are clinically diagnosed with Parkinson's disease.

Exclusion criteria

Exclusion criteria: 1) Suspected or confirmed secondary Parkinson's syndrome (vascular, pharmacological, traumatic, post encephalitis, toxic, etc.) (2) Suspected or confirmed atypical Parkinson's syndrome (progressive supranuclear palsy, multiple system atrophy, corticobasal ganglia degeneration, etc.) 3) A clear past history of stroke, moderate to severe traumatic brain injury, hydrocephalus, brain surgery or brain tumour 4) Severe cognitive impairment or psychiatric symptoms 5) Facial palsy, blepharospasm, myasthenia gravis, etc. causing facial expression muscles, ptosis, etc. affecting facial and eye movement capture. 6) Inability to co-operate in completing the test.

Design outcomes

Primary

Measure	Time frame
MDS-UPDRS-III;	—

Secondary

Measure	Time frame
Clinical characteristics;	—

Countries

China

Contacts

Public Contactliuzhenguo

Xinhua hospital affiliated to Shanghai Jiaotong University School of Medicine

liuzhenguo@xinhuamed.com.cn+86 21 2507 7501

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026